Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

T-cell levels and no detectable viral load on long-term HAART.  The trial has three dosing cohorts.  Subjects will remain on their existing antiviral therapy while receiving treatment with SB-728-T. A fourth cohort, of up to four subjects who have failed HAART and have measureable viral loads, was recently added to the study.  No data from subjects in the last two cohorts of this study were reported in today's CROI presentation. The primary objective of the study is to evaluate the safety and tolerability of SB-728-T. In addition to safety monitoring, data are being collected on the expansion, trafficking and persistence of SB-728-T, total CD4+ T-cell counts, CD4:CD8 T-cell ratios and viral load.

Dr. June has no financial relationship with Sangamo BioSciences, Inc.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate the safety and efficacy for the treatment of HIV/AIDS as well as a Phase 1 trial for the treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Today the U.S. Food and Drug Administration (FDA) announced ... serogroup B meningococcal disease in individuals ages ... received FDA approval in October, represent a significant step ... "I have heard over and over from parents ...
(Date:1/23/2015)... new analysis of Centers for Medicare and Medicaid Services, ... 81 percent of seniors chose lower-cost preferred pharmacy plans ... pharmacies. The findings were released by Drug Channels ... foundation of Medicare Part D," said Pharmaceutical Care Management ...
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) will ... KeyBanc Capital Markets 2011 Basic Materials ... InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... at the Grand Hyatt, New York, NY, presenting at ...
... SimonMed and Cox Business have partnered to make a ... patients in the Valley and across the state at ... is the first dedicated outpatient offering of breast tomosynthesis ... in Scottsdale. Sub-specialty trained radiologists at SimonMed ...
Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Responding to,conditions created by Hurricane Ike in ... and Manufacturers of America (PhRMA) has moved,from "alert" ... activation - as,part of its effort to ensure ... storm. PhRMA is working closely with other members ...
... trend over the past four months within High-Tech Medical Device, specifically ... a “recruiters” market causing both parties to change their ways of ... ... Group, an executive search firm, today reports a hiring trend over ...
... Cancer patients,in Indonesia will gain access to ... Memorandum of Understanding (MOU) today between Varian,Medical ... first private cancer hospital.,Under the MOU, Siloam ... a,collaborative relationship to explore opportunities for developing,innovative ...
... ARAY ), a global leader in the field of ... chief financial,officer and senior vice president to pursue other ... March 2008, has been,appointed to serve as senior vice ... successor is found., "Robert McNamara has been a ...
... 11 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... are scheduled to present at the 2008,UBS Life Sciences ... 2008 at the Grand Hyatt New York located at ... New York., To access the webcast, go to ...
... Blood,America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on,bringing the life saving potential of ... that CEO Matthew Schissler was interviewed,by Francis Gaskins, ... improving its market cap., The complete interview ...
Cached Medicine News:Health News:America's Pharmaceutical Research Companies Respond to Hurricane Ike's Imminent Landfall 2Health News:Lucas Group Reports Hiring Trend in High-Tech Medical Device 2Health News:Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia 2Health News:Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia 3Health News:Accuray Incorporated Announces Resignation of Chief Financial Officer 2Health News:Cord Blood America CEO Announces Aggressive Acquisition Strategy, Increased Investor Relations Efforts, New Stem Cell Storage Models 2
Medium Surgical Clips. 6 clips per cartridge. Box of 30 cartridges with a total of 180 titanium clips per box. For secure vasal and other occlusion....
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
Platinum General Purpose Cautery Electrodes , ,A - Loop Tip, ,Fully autoclavable. Tips typically last for 50 to 100 or more procedures, depending on burn time....
Medicine Products: